Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$11.02B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  TTNP
Titan Pharmaceuticals
TTNP
61 / 100
$7.32arrow_drop_up3.09%$0.22

Performance History

Stocklytics logo
Key Stats
Open$7.32
Prev. Close$7.10
EPS-7.41
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap6691735.00
PE Ratio-
LOWHIGH
Day Range7.32
7.32
52 Week Range5.00
16.60
Ratios
P/B Ratio1.00
Revenue-
Operating M. %-3,954.89%
Earnings$0.00
Earnings Growth %45.43%
EBITDA Margin %-
ROE %-139.14%
EPS-7.41

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

61vs 54. Market Avg.

All Score 61 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

TTNPMARKET
Value6540
Quality4140
Ownership2117
Growth6046
Dividends-38
check_circle

Titan Pharmaceuticals 's Price growth average in the last 3 years of 264.3% is great compared to market average of 5.49%. This indicates TTNP could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$726.31
24H (%)arrow_drop_down2.63%
24H ($)-$19.64
MARKET CAP$690.55B
PRICE$501.13
24H (%)arrow_drop_up1.61%
24H ($)$7.95
MARKET CAP$462.00B
PRICE$147.91
24H (%)arrow_drop_up1.48%
24H ($)$2.17
MARKET CAP$356.43B
PRICE$125.78
24H (%)arrow_drop_up0.43%
24H ($)$0.55
MARKET CAP$318.60B

About Titan Pharmaceuticals (TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David Elliot Lazar
Headquarters
South San Francisco
Employees
4
Exchange
NASDAQ
add Titan Pharmaceuticals  to watchlist

Keep an eye on Titan Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the market capitalization of Titan Pharmaceuticals (TTNP)?

Titan Pharmaceuticals (TTNP) has a market capitalization of $6.69M. The average daily trading volume is 6.42K, indicating the stock's liquidity and investor engagement.

help
What is Titan Pharmaceuticals 's (TTNP) price per share?

The current price per share for Titan Pharmaceuticals (TTNP) is $7.32. The stock has seen a price change of $0.22 recently, indicating a 3.1% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Titan Pharmaceuticals (TTNP)?

For Titan Pharmaceuticals (TTNP), the 52-week high is $16.6, which is 126.78% from the current price. The 52-week low is $5, the current price is 46.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Titan Pharmaceuticals (TTNP) a growth stock?

Titan Pharmaceuticals (TTNP) has shown an average price growth of 264.3% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Titan Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Titan Pharmaceuticals (TTNP) stock price performance year to date (YTD)?

As of the latest data, Titan Pharmaceuticals (TTNP) has a year-to-date price change of . Over the past month, the stock has experienced a price change of 6.24%. Over the last three months, the change has been 11.76%.

help
Is Titan Pharmaceuticals (TTNP) a profitable company?

Titan Pharmaceuticals (TTNP) has a net income of -$5.57M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 39.13% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.95K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $72K. Operating income is noted at -$7.28M. Furthermore, the EBITDA is -$7.16M.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.